The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Genentech; Lilly; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Genentech
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly; NCCN; Pfizer; Regeneron; Sirtex Medical; Taiho Pharmaceutical
Research Funding - NCCN; NCI; Oncolytics
Other Relationship - Exelixis; Polaris
 
Richard Hubner
Honoraria - Abbott Nutrition; Ipsen
Consulting or Advisory Role - BTG; Eisai; Shire
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Roche
 
Teresa Macarulla
Consulting or Advisory Role - Baxalta; Baxter; Celgene; Incyte; Ipsen; Lilly; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Shire
Research Funding - Agios (Inst); ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Merrimack (Inst); Millennium (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Merck; Sanofi; SERVIER
 
Andrew Scott Paulson
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Immunomedics
Honoraria - Cardinal Health
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Bristol-Myers Squibb; Eisai; Ipsen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); incyte (Inst); Ipsen (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Fiona Maxwell
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Yan Moore
Employment - Ipsen
Leadership - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Haofei Tiffany Wang
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Bin Zhang
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Patents, Royalties, Other Intellectual Property - Ipsen
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)